Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 5,152 Shares

Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 5,152 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total transaction of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Boston Scientific Corporation (NYSE:BSX) opened at $27.46 on Friday. The firm has a market cap of $37,710.00, a price-to-earnings ratio of 45.02, a P/E/G ratio of 1.96 and a beta of 0.96. Boston Scientific Corporation has a 12-month low of $23.03 and a 12-month high of $29.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting analysts’ consensus estimates of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.27 earnings per share. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.

Several equities research analysts have recently issued reports on the stock. SunTrust Banks set a $34.00 price objective on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Zacks Investment Research downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. BMO Capital Markets reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Tuesday, December 12th. Evercore ISI assumed coverage on shares of Boston Scientific in a research report on Wednesday, January 3rd. They issued an “in-line” rating and a $27.00 target price for the company. Finally, Needham & Company LLC raised shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and raised their target price for the company from $25.04 to $32.00 in a research report on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Boston Scientific currently has an average rating of “Buy” and an average price target of $31.00.

Hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC acquired a new stake in Boston Scientific in the third quarter valued at $138,000. Steward Partners Investment Advisory LLC acquired a new stake in Boston Scientific in the third quarter valued at $139,000. Acrospire Investment Management LLC lifted its stake in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 3,100 shares during the last quarter. San Francisco Sentry Investment Group CA acquired a new stake in Boston Scientific in the second quarter valued at $191,000. Finally, Ironwood Investment Counsel LLC acquired a new stake in Boston Scientific in the third quarter valued at $204,000. Hedge funds and other institutional investors own 90.36% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 5,152 Shares” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.com-unik.info/2018/01/13/boston-scientific-corporation-bsx-svp-david-a-pierce-sells-5152-shares.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

What are top analysts saying about Boston Scientific? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit